A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in Healthy Adults

Trial Profile

A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in Healthy Adults

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Apr 2017

At a glance

  • Drugs GSK 3389245A (Primary) ; Meningococcal vaccine group B OMV Novartis
  • Indications Respiratory syncytial virus infections
  • Focus Adverse reactions; First in man
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 25 Apr 2017 Results assessing safety and immunogenicity, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases
    • 02 Feb 2017 Planned End Date changed from 1 Jan 2017 to 1 Feb 2017.
    • 21 Apr 2016 Planned End Date changed from 1 Feb 2017 to 1 Jan 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top